Abstract：
UNASSIGNED: The treatment of failed ankle replacements is debated, and little is published about the medium- and long-term results of revision implants. We wanted to examine prosthesis survival and physical function at least 5 years after insertion of the Salto XT revision prosthesis.
UNASSIGNED: All consecutive patients operated with a Salto XT revision prosthesis underwent clinical and radiologic examinations preoperatively and after 3, 12, 24, and 60 months. Complications and reoperations are described, and changes in patient-reported outcome measures and clinical scores are reported.
UNASSIGNED: Thirty patients were operated with a Salto XT revision prosthesis between March 2014 and March 2017. Three of these were revised (1 to a fusion and 2 to a new prosthesis), and 3 patients were reoperated with screw removal. A concurrent subtalar fusion was performed on 13 patients, and there was 1 case of likely nonunion after these procedures, but no reoperations. The mean AOFAS score increased from 39.2 (95% CI 30.8-47.5) preoperatively to 75.1 (95% CI 67.3-82.9) after 5 years, and the mean improvement was 34.2 points (95% CI 23.8-44.6). Mean EQ-5D increased from 0.36 (95% CI 0.30-0.42) preoperatively to 0.74 (95% CI 0.64-0.85) after 5 years, an improvement of 0.34 (95% CI 0.19-0.49). Radiolucent lines were present in all but 3 patients. Five-year prosthesis survival was 93% (83.6-100).
UNASSIGNED: This is the first study to present medium-term results of this implant. We found good improvement in outcome scores and good implant survival, but also a high prevalence of radiolucent lines.
UNASSIGNED: All consecutive patients operated with a Salto XT revision prosthesis underwent clinical and radiologic examinations preoperatively and after 3, 12, 24, and 60 months. Complications and reoperations are described, and changes in patient-reported outcome measures and clinical scores are reported.
UNASSIGNED: Thirty patients were operated with a Salto XT revision prosthesis between March 2014 and March 2017. Three of these were revised (1 to a fusion and 2 to a new prosthesis), and 3 patients were reoperated with screw removal. A concurrent subtalar fusion was performed on 13 patients, and there was 1 case of likely nonunion after these procedures, but no reoperations. The mean AOFAS score increased from 39.2 (95% CI 30.8-47.5) preoperatively to 75.1 (95% CI 67.3-82.9) after 5 years, and the mean improvement was 34.2 points (95% CI 23.8-44.6). Mean EQ-5D increased from 0.36 (95% CI 0.30-0.42) preoperatively to 0.74 (95% CI 0.64-0.85) after 5 years, an improvement of 0.34 (95% CI 0.19-0.49). Radiolucent lines were present in all but 3 patients. Five-year prosthesis survival was 93% (83.6-100).
UNASSIGNED: This is the first study to present medium-term results of this implant. We found good improvement in outcome scores and good implant survival, but also a high prevalence of radiolucent lines.
摘要：
■踝关节置换失败的治疗存在争议，关于修复植入物的中期和长期结果的报道很少。我们希望在插入SaltoXT翻修假体至少5年后检查假体的存活率和身体功能。
■所有接受SaltoXT翻修假体手术的患者在术前和术后3、12、24和60个月接受临床和放射学检查。描述了并发症和再次手术，并报告患者报告的结局指标和临床评分的变化.
■在2014年3月至2017年3月期间，30例患者接受了SaltoXT翻修假体的手术。其中三个被修改（1个融合和2个新的假体），和3例患者再次手术拔除螺钉。对13例患者进行了距下融合，这些手术后有1例可能发生骨不连，但没有重复操作。5年后，平均AOFAS评分从术前的39.2（95％CI30.8-47.5）增加到75.1（95％CI67.3-82.9），平均改善为34.2点（95%CI23.8-44.6）。5年后，平均EQ-5D从术前的0.36（95％CI0.30-0.42）增加到0.74（95％CI0.64-0.85），改善0.34（95%CI0.19-0.49）。除3例患者外，所有患者均存在射线可透线。5年假体生存率为93%（83.6-100）。
■这是该植入物的中期结果的第一项研究。我们发现在结果评分和良好的植入物存活率方面有很好的改善，而且射线可透线的患病率很高。
■所有接受SaltoXT翻修假体手术的患者在术前和术后3、12、24和60个月接受临床和放射学检查。描述了并发症和再次手术，并报告患者报告的结局指标和临床评分的变化.
■在2014年3月至2017年3月期间，30例患者接受了SaltoXT翻修假体的手术。其中三个被修改（1个融合和2个新的假体），和3例患者再次手术拔除螺钉。对13例患者进行了距下融合，这些手术后有1例可能发生骨不连，但没有重复操作。5年后，平均AOFAS评分从术前的39.2（95％CI30.8-47.5）增加到75.1（95％CI67.3-82.9），平均改善为34.2点（95%CI23.8-44.6）。5年后，平均EQ-5D从术前的0.36（95％CI0.30-0.42）增加到0.74（95％CI0.64-0.85），改善0.34（95%CI0.19-0.49）。除3例患者外，所有患者均存在射线可透线。5年假体生存率为93%（83.6-100）。
■这是该植入物的中期结果的第一项研究。我们发现在结果评分和良好的植入物存活率方面有很好的改善，而且射线可透线的患病率很高。
